Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial

Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trialScientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’4-MIN READ4-MIN1ListenPublished: 10:00pm, 29 Jul 2026The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards.But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that scientists have long enjoyed in initiating clinical trials – a key mechanism behind China’s competitive edge in frontier treatments.02:53Chinese scientist under investigation after 6-year-old girl dies ‘following gene therapy’“I hope this tragedy does not have a lasting negative impact on China’s investigator-initiated clinical-research system, but there is a real risk of a regulatory backlash,” said Wang Haoran, chief executive of Neoland Biosciences, based in Shandong province.